Biotechnology News and Research

RSS

Examining the recent winners and losers in the health reform debate

"Pfizer Inc., the world's largest drugmaker, and hospital companies including Community Health Systems Inc. are benefiting from agreements with President Barack Obama that will limit any threat to their profits."

6 Oct 2009

Phase 2 clinical study results of TOPICA's luliconazole for athlete's foot announced

TOPICA Pharmaceuticals, a privately-held biotechnology company, today announced positive results from its Phase 2 clinical study evaluating luliconazole, one of the most potent and broad spectrum topical antifungal agents, in patients with tinea pedis (athlete's foot). The study was designed to assess the effectiveness of 1% luliconazole cream applied once daily for 14 days compared with once daily for 28 days.

6 Oct 2009

Sigma-Aldrich to distribute ThalesNano's CatCart catalyst products globally

Sigma-Aldrich announced today that it has signed a distribution agreement with ThalesNano, the world leader in bench top flow chemistry instruments, the terms of which will see Sigma-Aldrich distribute ThalesNano's complete line of approximately 400 CatCart® catalyst products for flow chemistry solutions on a global basis.

6 Oct 2009

NovImmune wins the 2009 EUROPEAN BIOTECHNICA AWARD

The winner of the 2009 EUROPEAN BIOTECHNICA AWARD is NovImmune SA from Switzerland. This biopharmaceutical company duly receives the lion’s share of the €100,000 prize money, which is awarded each year by Deutsche Messe AG and its partners. The aim of the award is to celebrate the achievements of innovative European companies in the field of biotechnology and the life sciences.

6 Oct 2009

Scientists expand their fleet of genomic next-generation sequencing technology to study about cancer

Scientists from the Baylor College of Medicine Human Genome Sequencing Center (HGSC) are expanding their fleet of advanced genomic next-generation sequencing technology from Applied Biosystems, part of Life Technologies Corporation to accelerate their studies of the genetic underpinnings of cancer and other complex human diseases.

6 Oct 2009

PDS Biotechnology's Versamune-based immunotherapy drug demonstrates safety in preclinical studies

PDS Biotechnology Corporation today announced that the company has completed GLP toxicology studies of its lead HPV-cancer product. The studies, which included pharmacokinetic (PK) and adsorption, bio-distribution and excretion (ADE) studies in addition to the evaluation of toxicity, all demonstrated a very safe profile of the drug and PDS Biotech's platform Versamune((TM)) technology.

6 Oct 2009

Ground Zero Pharmaceuticals opens new office in Brisbane

A major increase in innovative concepts for exciting therapeutic and preventive new products in Australia has led to an expansion of GZP's activities Down Under, to better support clients in their efforts to take their programs to the US Food and Drug Administration.

6 Oct 2009

Promising alternative to use of live animals for drug testing

International Stem Cell Corporation, the first company to perfect a method of creating human “parthenogenetic” stem cells from unfertilized eggs, announces positive results of its collaboration with Absorption Systems to study ISCO’s stem-cell-derived human corneal tissue as an alternative to live animals for drug testing.

6 Oct 2009

Biofuels are regulated under the Renewable Fuel Standard

Climate change legislation should not subject biofuels to double jeopardy in greenhouse gas emission regulation, since they are already regulated under the Renewable Fuel Standard.

6 Oct 2009

Ingenuity Systems, Millennium Science announce a multi-year deal for Ingenuity Pathway Analysis with QFAB

Ingenuity Systems, the leading provider of information solutions for life science researchers, and Millennium Science, Ingenuity Systems' exclusive distributor for Australia and New Zealand, today announced a multi-year deal for Ingenuity Pathway Analysis (IPA) with the Queensland Facility for Advanced Bioinformatics (QFAB).

6 Oct 2009

Scientia Advisors announces the results of an in-depth study of the changing vaccine industry

Technological breakthroughs, national immunization programs and emerging vaccines for treating, rather than preventing, disease are priming the global vaccine market for growth.

6 Oct 2009

SEC completes investigation of PharmaNet Development, no action recommended

PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, today announced that the United States Securities and Exchange Commission (SEC) has notified the Company that it has completed a two and half year investigation of the Company related to revenue recognition, earnings, company operations and related party transactions and does not intend to recommend any enforcement action by the Commission. The investigation, which is now closed, was originally initiated as an informal investigation in 2006 and became formal in March 2007.

6 Oct 2009

Vivaldi receives US patent for live attenuated influenza vaccines

Vivaldi Biosciences Inc. (Vivaldi), a biotechnology company focused on development of vaccines for influenza, today announced that the United States Patent and Trademark Office has issued US Patent 7,588,768 covering live attenuated influenza vaccines (LAIVs) with modifications to the viral NS1 gene, and methods for producing the vaccines in cell culture systems.

6 Oct 2009

NTU launches research centre to help sustain Earth's environment

The Nanyang Technological University (NTU) launches a first-of-its-kind research centre in Singapore focussing on research in recovering resources from waste.

6 Oct 2009

Illumina launches IlluminaCompute for its Genome Analyzer sequencing platform

At the BioIT World Europe Conference, Illumina, Inc. announced the launch of IlluminaCompute, a fully integrated computing solution for its Genome Analyzer sequencing platform.

From Illumina, Inc. 6 Oct 2009

Key defence mechanism used by the immune system against Listeria identified

A team of University of British Columbia microbiologists has identified a key defence mechanism used by the immune system against Listeria with strong implications for the future development of vaccines.

6 Oct 2009

Inviragen, SingVax merge their complementary vaccine pipelines

Inviragen and SingVax have merged their complementary vaccine pipelines and their international product development capabilities to create a company that is developing a wide range of vaccines for infectious diseases prevalent in emerging economies.

6 Oct 2009

ThromboGenics presents Phase IIa microplasmin intravitreal injection trial results at the ASRS conference

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative medicines for eye disease, vascular disease and cancer, today announces results of a Phase IIa trial evaluating microplasmin intravitreal injection for the treatment of Diabetic Macular Edema (MIVI II DME).

6 Oct 2009

US Oncology to exhibit its oncology-specific EHR system at the 2009 ASCO symposium

US Oncology, Inc. plans to exhibit its oncology-specific electronic health record (EHR) system, iKnowMed, at the American Society of Clinical Oncology's (ASCO) 2009 EHR Symposium: Harnessing the EHR: From Incentives to Sustainability, October 6-7 in San Francisco.

6 Oct 2009

YM BioSciences to acquire Cytopia

Cytopia Limited has today announced that Cytopia and Toronto-based YM BioSciences Inc. ("YM") have signed an exclusive and binding Implementation Agreement ("Agreement") in which it is proposed that YM will acquire all of the issued shares and options in Cytopia.

6 Oct 2009